Dysregulation of cellular glycosylation is a common characteristic of many cancers (1). The T antigen (Galβ1,3-GalNAcα1-O-Ser/Thr ) is up-regulated in a wide variety of cancers (2, 3), and has been investigated as a diagnostic & prognostic marker, and as a therapeutic and vaccine (4, 5). The specificity of the anti-T monoclonal antibody was shown by binding to asialo-fetuin, which presents the T antigen, and not to fetuin, in which the T antigen is capped by sialic acid residues (3). This antibody was previously marketed under HB-T (6).
- Hakomori, S. (1996) Cancer Res. 56, 5309.
- Springer, G.F. (1984) Science 224, 1198.
- Kjeldsen, T. et al. (1988) Cancer Res. 48, 2214.
- Desai, P. (2000) Transfusion Med. Rev. 14, 312-25.
- Springer, G.F. (1997) J. Mol. Med. 75, 594.
- Marcos, N.T. et al. (2004) Cancer Res. 64, 7050.
Preparation: Monoclonal antibodies were produced from the mouse hybridoma 3C9 clone (HB-T).
Purification: Three step liquid chromatography, proprietary.
Catalog #: SBH-T
Formulation: Sterile filtered solution PBS.
Stability: Stable for 4 weeks at 4C. Stable for 6 months at -80C. Avoid repeated freeze-thaw cycles.
Specificity Assay: To create asialo Fetuin (aFet), 5mg of Fetuin (Sigma F3004) was treated with 2U of Neuraminidase (Sigma N2876) for 2 hrs at 37⁰C. Double dilution ELISAs were carried out by coating 96 well plates with a 1:3 serial dilution of 67ug/ml Fet or aFet, blocking and incubating with a 1:3 serial dilution of anti-T (SBH-T). After washing, plates were incubated with a goat-anti-mouse (IgG+IgM)-HRP conjugate (Thermo 31446) at 1:1000 dilution. Plates were developed with 2x ABTS (Southern Biotech 0202-01). Net OD was measured at 405 – 650 nm. SBH-T MAb diluted 10 fold could detect aFet coated at 22 ug/ml, with 200 fold less signal for Fet (see Figure 1 panel (B) above).
Usage: For research only. Not for use in diagnostic or therapeutic procedures.
Country of Origin: USA
We are open for suggestions and would be pleased to hear from you.